DENTSPLY SIRONA (NASDAQ:XRAY) Upgraded at Zacks Research

Zacks Research upgraded shares of DENTSPLY SIRONA (NASDAQ:XRAY) from a strong sell rating to a hold rating in a research note released on Monday morning,Zacks.com reports.

XRAY has been the topic of several other research reports. Barrington Research increased their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Wells Fargo & Company increased their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. UBS Group decreased their price target on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $13.00 to $17.00 in a research report on Thursday, February 19th. Three equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $14.42.

DENTSPLY SIRONA Price Performance

Shares of DENTSPLY SIRONA stock opened at $13.44 on Monday. The firm has a market capitalization of $2.68 billion, a PE ratio of -4.48, a price-to-earnings-growth ratio of 1.56 and a beta of 0.97. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA has a 12 month low of $9.85 and a 12 month high of $17.18. The business’s 50-day moving average price is $12.56 and its 200-day moving average price is $12.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts forecast that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 26th were issued a $0.16 dividend. The ex-dividend date was Friday, December 26th. This represents a $0.64 annualized dividend and a yield of 4.8%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is -21.33%.

Insiders Place Their Bets

In other news, Director Gregory T. Lucier bought 22,445 shares of DENTSPLY SIRONA stock in a transaction on Tuesday, March 3rd. The shares were purchased at an average price of $14.03 per share, for a total transaction of $314,903.35. Following the acquisition, the director owned 50,000 shares of the company’s stock, valued at approximately $701,500. The trade was a 81.46% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in DENTSPLY SIRONA during the fourth quarter valued at $302,000. Compound Planning Inc. bought a new position in shares of DENTSPLY SIRONA in the 4th quarter worth about $117,000. Invesco Ltd. lifted its position in DENTSPLY SIRONA by 101.1% during the 4th quarter. Invesco Ltd. now owns 1,063,523 shares of the medical instruments supplier’s stock valued at $12,156,000 after acquiring an additional 534,714 shares during the period. Michels Family Financial LLC boosted its stake in DENTSPLY SIRONA by 8.9% during the fourth quarter. Michels Family Financial LLC now owns 41,989 shares of the medical instruments supplier’s stock worth $480,000 after acquiring an additional 3,422 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC purchased a new stake in DENTSPLY SIRONA in the fourth quarter worth about $680,000. 95.70% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director purchases: Long‑time director Gregory T. Lucier bought sizable blocks of stock on March 2 and March 3 (27,555 shares at ~$14.24 and 22,445 shares at ~$14.03), raising his ownership to ~50,000 shares — a strong insider confidence signal. InsiderTrades Article
• Positive Sentiment: Barrington Research raised its price target to $17 — an upbeat analyst action that implies meaningful upside relative to current levels and can attract buyer interest. Barrington Research PT Raise
• Positive Sentiment: Zacks upgraded XRAY from “strong sell” to “hold,” removing a negative rating and potentially supporting short‑term sentiment improvement. Zacks Upgrade
• Neutral Sentiment: Mizuho raised its price target to $16 but left a “neutral” rating — modestly positive for price targets but limited catalyst without a rating upgrade. Mizuho Note
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference (Mar 10) — a scheduled event that could provide fresh guidance or color but is not itself a guaranteed catalyst. Conference Notice
• Neutral Sentiment: Fundamental watch‑items: Coverage notes flag international revenue trends and mixed analyst targets (average PT ~$14.42) — useful context for modeling but neither clearly bullish nor bearish on its own. Zacks Analysis
• Neutral Sentiment: Short‑interest reporting appears anomalous (reports showing zero/NaN), so treat any short‑squeeze narratives as unreliable until corrected data is posted.
• Negative Sentiment: Earnings & guidance caveat: The company slightly missed quarterly EPS consensus (by ~$0.01) despite a revenue beat, and FY‑2026 guidance (1.40–1.50 EPS) sits below some sell‑side estimates (~1.84), which could cap upside if analysts lower forecasts. MarketBeat Summary

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.